文献速递肾移植急性肾损伤

ABO血型不相容活体肾移植术后早期血栓性微血管病

Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation.
PubMed 文献 · Kidney Int Rep · 2024-12-30

该多中心回顾性研究纳入2013至2022年间375例ABO血型不相容活体肾移植受者,其中23例(6.1%)在术后早期发生血栓性微血管病(TMA),中位发生时间为1天。TMA组移植前IgG和IgM抗血型抗体滴度显著更高,移植前IgG≥1/8和IgM≥1/4可独立预测TMA发生,8例(30.4%)发生早期移植物丢失。

要点

  • ABO血型不相容肾移植术后早期TMA发生率为6.1%,中位发生时间为术后1天。
  • 移植前IgG≥1/8和IgM≥1/4是TMA发生的独立预测因素。
  • TMA组早期移植物丢失率达30.4%,中位丢失时间为7天。

核心结论

  • ABO血型不相容肾移植术后TMA并非罕见现象,在治疗无应答患者中预后较差。
  • 血凝法检测的抗血型抗体滴度是TMA发生的不完美预测标志物。

研究设计与样本

  • 多中心回顾性研究,纳入2013至2022年间375例ABO血型不相容活体肾移植受者。
  • 比较术后1个月内发生TMA(组织学和/或生物学)的23例患者与初始病程顺利且活检正常的匹配对照。

主要发现

  • 23例早期移植肾活检中17例(80.9%)有活动性TMA的组织学证据。
  • TMA组移植前IgG和IgM抗血型抗体峰值及末次检测水平均显著更高(峰值IgG P=0.01,IgM P=0.0006;移植前末次检测IgG P<0.0001,IgM P=0.0003)。
  • 8例(30.4%)发生早期移植物丢失,中位时间为7天(IQR 3-16天)。

关键数值与推荐

  • 移植前IgG≥1/8和IgM≥1/4可显著且独立预测TMA发生。
  • 未发现其他预测因素。

临床怎么用

  • ABO血型不相容肾移植术后早期应警惕TMA,尤其移植前抗血型抗体滴度较高者。
  • 治疗包括血浆置换和依库珠单抗,但部分患者仍出现早期移植物丢失。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although long-term graft survival is comparable with that of ABO-compatible (ABOc) renal transplantation, the risk of antibody-mediated rejection (ABMR) following ABO-incompatible (ABOi) transplantation is higher and can occur as an early thrombotic microangiopathy (TMA). METHODS: We designed a retrospective multicenter study, including all patients who presented with a TMA (histological and/or biological) after an ABOi transplantation (< 1 month) and compared with matched controls who had a favorable initial course with a normal biopsy. RESULTS: Between 2013 and 2022, 375 ABOi kidney transplants were performed and 23 patients (6.1%) developed TMA (median: 1 day, interquartile range [IQR]: 0-3 days). Twenty-one patients (91.3%) had biological TMA. Among 23 early graft biopsies, histological evidence of active TMA was found in 17 cases (80.9%). All patients received treatment: 20 of 23 received at least 1 session of plasmapheresis and 19 of 23 received at least 1 injection of eculizumab. Eight early graft losses (30.4%) occurred (median: 7 days, IQR: 3-16 days). IgG and IgM anti-blood group antibody (ABGA) levels (peak and last pregraft assay) were significantly higher in the TMA group (peak: P = 0.01 for IgG and P = 0.0006 for IgM; last assay before kidney transplantation [KT]: P < 0.0001 for IgG and P = 0.0003 for IgM). A level ≥ 1/8 for IgG and ≥ 1/4 or IgM before transplantation were significantly and independently predictive of the occurrence of TMA. No other predictive factors were found. CONCLUSION: TMA after ABOi transplantation is not a rare phenomenon and is associated with a poor prognosis in nonresponders-to-treatment patients. ABGA titer performed by hemagglutination is an imperfect marker of the occurrence of such a phenomenon.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Bertrand D, Del Bello A, Sberro Soussan R, et al. Early Thrombotic Microangiopathy After ABO-Incompatible Living Donor Kidney Transplantation. Kidney Int Rep. 2024. PMID: 40225375. doi:10.1016/j.ekir.2024.12.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。